![Steven Kelly](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 32 $ in data 31/08/2026
Mr. Steven Kelly is a Chief Executive Officer & Director at Actithera, Inc. and an Independent Director at Artelo Biosciences, Inc. He is on the Board of Directors at Actithera, Inc. and Artelo Biosciences, Inc. Mr. Kelly was previously employed as a Chief Executive Officer by Carisma Therapeutics, Inc., a President, Chief Executive Officer & Director by Carisma Therapeutics, Inc., a President & Chief Executive Officer by CTx Operations, Inc., a President & Chief Executive Officer by Pinteon Therapeutics, Inc., a Principal by Kelly Bioconsulting LLC, a Chief Executive Officer by Theracrine, Inc., a Chief Commercial Officer by BioVex, Inc., and a President & Chief Executive Officer by Innovive Pharmaceuticals, Inc. He received his undergraduate degree from the University of Oregon and an MBA from Cornell University.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 17/07/2026 | 5 ( 0% ) | 32 $ | 31/08/2026 | |
| 31/05/2025 | 0 ( -.--% ) | - $ | 31/08/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| ARTELO BIOSCIENCES, INC. | Direttore/Membro del Consiglio | 02/05/2017 |
Actithera, Inc.
 Actithera, Inc. Pharmaceuticals: MajorHealth Technology Develops radioactive isotopes molecules for treatment of cancer | Amministratore Delegato | 10/09/2026 |
| Società | Posizione | Fine |
|---|---|---|
| CARISMA THERAPEUTICS, INC. | Amministratore Delegato | 01/01/2026 |
| CARISMA THERAPEUTICS, INC. | Amministratore Delegato | 15/11/2025 |
CTx Operations, Inc.
 CTx Operations, Inc. BiotechnologyHealth Technology Develops macrophage-based immunotherapeutic for treatment of cancer | Amministratore Delegato | 01/11/2025 |
Kelly Bioconsulting LLC
 Kelly Bioconsulting LLC Miscellaneous Commercial ServicesCommercial Services Provides business consulting services | Corporate Officer/Principal | 01/01/2018 |
Pinteon Therapeutics, Inc.
 Pinteon Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops therapeutics for cancer treatment | Amministratore Delegato | 01/07/2015 |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 11 |
|---|---|
BioVex, Inc.
 BioVex, Inc. Pharmaceuticals: MajorHealth Technology Develops vaccines for the treatment of cancer and the prevention of chronic infectious diseases | Health Technology |
Innovive Pharmaceuticals, Inc.
 Innovive Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceutical products | Health Technology |
Pinteon Therapeutics, Inc.
Pinteon Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops therapeutics for cancer treatment | Health Technology |
Artelo Biosciences, Inc.
 Artelo Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company that develops endocannabinoid system modulating therapeutics | Health Technology |
Cornell University
 Cornell University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Oregon
 University of Oregon Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Theracrine, Inc.
 Theracrine, Inc. BiotechnologyHealth Technology Develops anti-metastatic drugs for cancer therapeutics | Health Technology |
CTx Operations, Inc.
CTx Operations, Inc. BiotechnologyHealth Technology Develops macrophage-based immunotherapeutic for treatment of cancer | Health Technology |
Kelly Bioconsulting LLC
Kelly Bioconsulting LLC Miscellaneous Commercial ServicesCommercial Services Provides business consulting services | Commercial Services |
Carisma Therapeutics, Inc.
 Carisma Therapeutics, Inc. BiotechnologyHealth Technology Develops novel chimeric antigen receptor macrophage and CAR-monocyte technology treatment of non-muscle invasive bladder cancer | Health Technology |
Actithera, Inc.
Actithera, Inc. Pharmaceuticals: MajorHealth Technology Develops radioactive isotopes molecules for treatment of cancer | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
